EpiBone creates a personalized 'scaffold' of the required replacement bone and, using a custom bioreactor and stem cells from your body, 'incubate' a new bone and remodels it as a personalised bone graft

NetScientific PLC (AIM:NSCI) said it is investing a further US$1mln (750,000) into portfolio company EpiBone Inc.whichdeveloped a revolutionary process to regenerate bone and cartilage.

The investment is made up of US$734k from the AIM companys balance sheet and US$266,000 in advised funds from its corporate finance and venture capital subsidiary EMV Capital Ltd.

Part of a wider US$11m funding round, Netscientific said thecash should fund theUS-based EpiBone through to a scale-up funding round expected in late 2022 and enable the company to accelerate development of its pipeline.

We see EpiBone as an emerging leader in the regenerative medicine space, which is now coming of age,"Dr Ilian Iliev, chief executive of NetScientificsaid.

Its platform technology has the potential to transform the bone and cartilage space by making implants from patients' own cells across multiple applications. This is another example of NetScientific's judicious investment approach to build stakes in businesses, and supporting its trans-Atlantic model, as it accelerates the portfolio company growth to deliver superior investment returns.

EpiBones lead bone product, EB-CMF, is now in Phase 1 human trials after being granted Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) in 2019.

Its three-step technology starts with a CT scan to determine the exact 3D size and shape of the bone needed for the defect being treated, together with extraction of adult stem cells.

The second stage involves the creation of a precise, personalized scaffold of the required boneand the design and construction of a custom bioreactor that will incubate the new bone as it grows.

The final stage involves infusion of the stem cells into the scaffoldand growth inside the bioreactor where they are remodelled into a personalized bone graft ready for implantation.

EpiBone chief executive Nina Tandon said the new funding will provide not only investment, but also value added skills and channels for EpiBone to grow internationally.

More:

NetScientific backs bone-regrowth innovator with US$1mln follow-on investment - Proactive Investors UK

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh